CLOs on the Move

Health Partners Central Minnesota Clinics

www.hpcmc.com

 
Health Partners Central Minnesota Clinics is a Saint Cloud, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.hpcmc.com
  • 1245 15th St N
    Saint Cloud, MN USA 56303
  • Phone: 800.370.0570

Executives

Name Title Contact Details

Similar Companies

Orbit Health

Digital Health Information Management provider for Sub-Saharan Africa.

Holy Family Manor Inc

Holy Family Manor Inc is a Orwigsburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chiltern

We are the leading, global mid-sized contract research organization. Our team of more than 4,200 employees working across 47 countries delivers collaborative clinical development services and solutions Designed Around You®.

Planned Parenthood of Orange and San Bernardino Counties

Planned Parenthood is the leading provider of reproductive health care in the country. At Planned Parenthood of Orange and San Bernardino Counties, we fight for the fundamental right of all individuals to determine their own destiny.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.